Methicillin-resistant Staphylococcus aureus (MRSA) is an antibiotic resistant strains of bacteria. MRSA infections are classified as hospital-acquired (HA-MRSA) or community-acquired (CA-MRSA). MRSA causes various infections such as skin infections, bone and joint infections, bacteremia, animal infections, and others.
The global MRSA drugs market is driven by several factors such as growing number of hospitals and expanding healthcare facilities, growing demand for antibacterial drugs due to steady growth in the elderly and the immune compromised population, growing awareness by government programmes to control MRSA, and growing prevalence rate of MRSA.
Get a Sample report at https://www.marketresearchfuture.com/sample_request/2102 .
Key Players in the Global MRSA Drugs Market
Some of the key players profiled in the report are Merck KGaA, Olon, Allergan, Baxter, Theravance Biopharma, Pfizer, Mylan N.V and Novartis and others.
The Americas accounts for a significant market share owing to high expenditure on the health care. Additionally, the fastest uptake of new drugs in the US drives the MRSA drugs market. Furthermore, concentration of the major healthcare companies in the developed countries of this region coupled with large insurance penetration is adding fuel to the market growth. Moreover, the US expend high amount on its healthcare, which accounts for 16% of total GDP that also increases the sale in MRSA drugs market.
Europe is the second largest market in the world due to high income and strong healthcare penetration. The European market growth is led by countries such as Germany and France. Italy is expected to be the fastest growing market over the assessment period. The strong pharmaceutical industry in Germany is a strong driver behind the dominance of this country in Europe. Southern European MRSA market is growing at a higher rate as compared to Scandinavian region countries such as Iceland, Norway.
Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to the fast growing healthcare sector and large unmet needs over the forecast period. However, Asian countries such as Indonesia, Vietnam, Japan, South Korea, Philippines, Sri Lanka, etc. have higher prevalence and are expected to contribute highly to the market growth. The growing penetration of healthcare insurance in the Asia Pacific region is expected to drive the future MRSA drugs market in the region.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt, and Iran. The African region is expected to witness a moderate growth owing to poor economic and political conditions, and poor healthcare development.
- Oxazolidinones segment commanded the largest market share in 2016 and is expected to reach USD 1,393.5 million by the end of 2023. Furthermore, Oxazolidinones segment is expected to be the fastest growing market, which is expected to grow at a CAGR of 5.1 % during the forecast period 2017-2023.
- Hospital-acquired (HA-MRSA) segment commanded the largest market share in 2016. This market is expected to reach USD 2,709.5 million by 2023 at a CAGR of 4.0 % during the forecast period 2017-2023.
- Skin infections segment commanded the largest market share in 2016. This market is expected to reach USD 1,208.3 million by 2023 at a CAGR of 4.5 % during the forecast period 2017-2023
- North America commanded the largest market share in 2016. This market is expected to reach USD 1,602.5 million by 2023 at a CAGR of 4.6 % during the forecast period of 2017-2023
Browse Complete Report at https://www.marketresearchfuture.com/reports/mrsa-drugs-market-2102 .
The global MRSA drugs market has been segmented on the basis of drug class, MRSA types, disease indications, and end user.
Based on the drug class, the market has been segmented as sulfa drugs, tetracyclines, oxazolidinones, glycopeptide antibiotics, and other.
Based on the MRSA types, the market has been segmented as hospital-acquired (HA-MRSA), and community-acquired (CA-MRSA).
Based on the disease indications, the market has been segmented as skin infections, bone and joint infections, bacteremia, animal infections, and others.
Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.
Market Research Future
+1 646 845 9312